Belzutifan Disease Interactions
There are 4 disease interactions with belzutifan.
Belzutifan (applies to belzutifan) anemia
Moderate Potential Hazard, Moderate plausibility.
Belzutifan can cause severe anemia that can require a blood transfusion. Patients should be monitored for anemia before starting treatment. Withhold treatment in patients with hemoglobin below 9 g/dL. Transfuse patients as clinically indicated. Close monitoring is advised during treatment.
Belzutifan (applies to belzutifan) hypoxia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment
Belzutifan can cause severe hypoxia. Oxygen saturation should be monitored before treatment initiation. Withhold treatment if pulse oximeter is less than 88% or PaO2 is 55 mmHg or less. Monitor patients closely during treatment, administer oxygen or hospitalize as clinically needed. Treatment may need to be suspended or discontinued depending on the severity of the hypoxia.
Belzutifan (applies to belzutifan) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Belzutifan has not been studied in patients with moderate and severe hepatic impairment. Caution is advised. No dosage modification is required in patients with mild hepatic impairment.
Belzutifan (applies to belzutifan) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Belzutifan has not been studied in patients with severe renal impairment. Caution is advised. No dosage modification is required in patients with mild or moderate renal impairment.
Switch to professional interaction data
Belzutifan drug interactions
There are 400 drug interactions with belzutifan.
Report options
More about belzutifan
- belzutifan consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Lenvima
Lenvima (lenvatinib) is used to treat thyroid cancer, advanced renal cell carcinoma, hepatocellular ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Lenvatinib
Lenvatinib is used to treat thyroid cancer, kidney cancer, liver cancer, and advanced endometrial ...
Everolimus
Everolimus (Afinitor, Afinitor Disperz, Zortress) belongs to a class of drugs called kinase ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
